Loading...

Halozyme Therapeutics

DB:RV7
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RV7
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. The last earnings update was 62 days ago. More info.


Add to Portfolio Compare Print
RV7 Share Price and Events
7 Day Returns
-1.4%
DB:RV7
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-3.9%
DB:RV7
-7.4%
DE Biotechs
-5.6%
DE Market
RV7 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Halozyme Therapeutics (RV7) -1.4% 7.3% 5.7% -3.9% 48.4% 174.5%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • RV7 outperformed the Biotechs industry which returned -7.4% over the past year.
  • RV7 outperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
RV7
Industry
5yr Volatility vs Market

Value

 Is Halozyme Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Halozyme Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Halozyme Therapeutics.

DB:RV7 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:RV7
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (5.32%))
1.344
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.34
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.344 * 5.96%)
8.24%

Discounted Cash Flow Calculation for DB:RV7 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Halozyme Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:RV7 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.24%)
2019 -42.00 Analyst x2 -38.80
2020 -20.00 Analyst x1 -17.07
2021 59.00 Analyst x1 46.52
2022 207.00 Analyst x1 150.80
2023 370.00 Analyst x1 249.03
2024 516.68 Est @ 39.64% 321.29
2025 660.42 Est @ 27.82% 379.40
2026 789.48 Est @ 19.54% 419.02
2027 898.01 Est @ 13.75% 440.34
2028 985.05 Est @ 9.69% 446.24
Present value of next 10 years cash flows $2,396.77
DB:RV7 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $985.05 × (1 + 0.23%) ÷ (8.24% – 0.23%)
$12,322.33
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $12,322.33 ÷ (1 + 8.24%)10
$5,582.21
DB:RV7 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,396.77 + $5,582.21
$7,978.98
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $7,978.98 / 144.90
$55.06
DB:RV7 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:RV7 represents 0.87769x of NasdaqGS:HALO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87769x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 55.06 x 0.87769
€48.33
Value per share (EUR) From above. €48.33
Current discount Discount to share price of €14.39
= -1 x (€14.39 - €48.33) / €48.33
70.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Halozyme Therapeutics is available for.
Intrinsic value
>50%
Share price is €14.39 vs Future cash flow value of €48.33
Current Discount Checks
For Halozyme Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Halozyme Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Halozyme Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Halozyme Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Halozyme Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RV7 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.56
NasdaqGS:HALO Share Price ** NasdaqGS (2019-04-24) in USD $16.4
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Halozyme Therapeutics.

DB:RV7 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:HALO Share Price ÷ EPS (both in USD)

= 16.4 ÷ -0.56

-29.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Halozyme Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Halozyme Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Halozyme Therapeutics's expected growth come at a high price?
Raw Data
DB:RV7 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -29.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
56.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Halozyme Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Halozyme Therapeutics's assets?
Raw Data
DB:RV7 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.72
NasdaqGS:HALO Share Price * NasdaqGS (2019-04-24) in USD $16.4
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:RV7 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:HALO Share Price ÷ Book Value per Share (both in USD)

= 16.4 ÷ 1.72

9.51x

* Primary Listing of Halozyme Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Halozyme Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Halozyme Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Halozyme Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Halozyme Therapeutics expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
56.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Halozyme Therapeutics expected to grow at an attractive rate?
  • Halozyme Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Halozyme Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Halozyme Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:RV7 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RV7 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 56.3%
DB:RV7 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 25.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RV7 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RV7 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 616 306 3
2022-12-31 483 140 3
2021-12-31 315 33 4
2020-12-31 209 -19 -82 7
2019-12-31 209 -46 -66 7
DB:RV7 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 152 -50 -80
2018-09-30 281 93 46
2018-06-30 319 132 76
2018-03-31 318 134 68
2017-12-31 317 134 63
2017-09-30 166 -35 -88
2017-06-30 134 -64 -120
2017-03-31 134 -60 -116
2016-12-31 147 -50 -103
2016-09-30 160 -50 -71
2016-06-30 149 -58 -67
2016-03-31 159 -36 -37

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Halozyme Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Halozyme Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RV7 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Halozyme Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RV7 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.87 2.28 1.46 2.00
2022-12-31 0.88 1.34 0.54 3.00
2021-12-31 0.01 0.40 -0.37 4.00
2020-12-31 -0.51 -0.22 -0.87 6.00
2019-12-31 -0.45 -0.39 -0.55 8.00
DB:RV7 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.56
2018-09-30 0.32
2018-06-30 0.54
2018-03-31 0.49
2017-12-31 0.46
2017-09-30 -0.66
2017-06-30 -0.93
2017-03-31 -0.91
2016-12-31 -0.81
2016-09-30 -0.56
2016-06-30 -0.52
2016-03-31 -0.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Halozyme Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Halozyme Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Halozyme Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Halozyme Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Halozyme Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Halozyme Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Halozyme Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Halozyme Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Halozyme Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Halozyme Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RV7 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 151.86 -80.33 60.80
2018-09-30 281.19 45.68 57.54
2018-06-30 319.37 76.28 56.01
2018-03-31 317.92 68.41 54.76
2017-12-31 316.61 62.97 53.82
2017-09-30 166.05 -88.30 51.27
2017-06-30 134.17 -119.99 49.54
2017-03-31 133.76 -116.10 47.66
2016-12-31 146.69 -103.02 45.85
2016-09-30 159.92 -71.32 44.22
2016-06-30 148.84 -66.83 42.84
2016-03-31 158.89 -36.94 41.44
2015-12-31 135.06 -32.23 40.03
2015-09-30 113.21 -41.82 37.69
2015-06-30 107.03 -37.64 36.05
2015-03-31 82.03 -56.94 34.99
2014-12-31 75.33 -68.38 35.84
2014-09-30 57.46 -85.09 36.95
2014-06-30 58.86 -84.10 36.49
2014-03-31 54.93 -90.74 35.04
2013-12-31 54.80 -83.48 32.35
2013-09-30 64.09 -65.90 29.97
2013-06-30 53.41 -66.61 27.47
2013-03-31 46.72 -57.72 25.75
2012-12-31 42.33 -53.55 24.81
2012-09-30 22.94 -67.56 23.70
2012-06-30 40.55 -42.39 22.33

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Halozyme Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Halozyme Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Halozyme Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Halozyme Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Halozyme Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Halozyme Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Halozyme Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Halozyme Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Halozyme Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Halozyme Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Halozyme Therapeutics Company Filings, last reported 3 months ago.

DB:RV7 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 248.89 126.38 354.53
2018-09-30 239.74 146.46 364.37
2018-06-30 254.93 166.05 398.89
2018-03-31 265.06 185.16 433.69
2017-12-31 208.37 202.35 469.21
2017-09-30 72.39 206.85 316.92
2017-06-30 58.17 211.03 297.53
2017-03-31 -58.50 214.03 178.99
2016-12-31 -32.48 216.62 204.98
2016-09-30 -11.99 212.20 221.05
2016-06-30 9.92 208.14 229.99
2016-03-31 29.47 196.02 238.64
2015-12-31 43.00 49.83 108.34
2015-09-30 31.80 49.79 123.72
2015-06-30 50.23 49.75 140.72
2015-03-31 37.55 49.72 128.50
2014-12-31 41.35 49.86 135.62
2014-09-30 39.94 49.84 134.46
2014-06-30 55.30 49.82 147.65
2014-03-31 66.75 49.79 164.49
2013-12-31 -19.99 49.77 71.50
2013-09-30 -3.49 32.30 65.31
2013-06-30 11.14 31.82 76.01
2013-03-31 31.68 31.14 87.43
2012-12-31 48.85 31.11 99.50
2012-09-30 51.19 0.00 87.61
2012-06-30 69.23 0.00 102.04
  • Halozyme Therapeutics's level of debt (50.8%) compared to net worth is high (greater than 40%).
  • Halozyme Therapeutics had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Halozyme Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Halozyme Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -68.7% each year.
X
Financial health checks
We assess Halozyme Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Halozyme Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Halozyme Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Halozyme Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Halozyme Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Halozyme Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Halozyme Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RV7 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RV7 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Halozyme Therapeutics has not reported any payouts.
  • Unable to verify if Halozyme Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Halozyme Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Halozyme Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Halozyme Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Halozyme Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Halozyme Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Halozyme Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Halozyme Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Helen Torley
COMPENSATION $5,799,669
AGE 55
TENURE AS CEO 5.3 years
CEO Bio

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. Prior to joining Halozyme in January 2014, she served as the Chief Commercial Officer and Executive Vice President of Onyx Pharmaceuticals, Inc. since August 29, 2011, where she oversaw the collaboration with Bayer on Nexavar® and Stivarga® and the U.S. launch of Kyprolis. Dr. Torley served as Vice President and General Manager of Nephrology Business Unit at Amgen Inc. since October 2003 to 2011. She joined Amgen Inc. on June 2002 as Therapeutic Area Head of Inflammation Global Marketing. She serves as the Chief Commercial Officer and Executive Vice President at Onyx Pharmaceuticals Internatiaonal GmbH. Dr. Torley served as Chief Operating Officer of Onyx Pharmaceuticals, Inc. She has been a Director of Quest Diagnostics Inc. since May 17, 2018. She began her industry career at Sandoz/Novartis in 1990, heading up the clinical development program for Sand immune in rheumatoid arthritis. During her 7 years at Novartis, she held positions of increasing responsibility in medical marketing and marketing, ultimately serving as Vice President of Medical Affairs, with responsibility for medical marketing and phase IIIB/IV trials across all therapeutic areas. In 1997, Dr. Torley joined Bristol-Myers Squibb and held various positions, including Regional Vice President of cardiovascular and metabolic sales, heading up the 150 sales representatives from the California sales team. She was Senior Registrar in rheumatology at the Royal Infirmary, Glasgow, Scotland. Dr. Torley has board significant industry experience and deep knowledge and expertise in development and commercialization of biopharmaceutical products, including several recent successful product launches. She has been a Director of Relypsa, Inc. since January 2015 and Halozyme Therapeutics, Inc. since January 6, 2014. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B) from University of Glasgow in 1984 and her MRCP in 1987.

CEO Compensation
  • Helen's compensation has increased whilst company is loss making.
  • Helen's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Halozyme Therapeutics management team in years:

2.8
Average Tenure
55
Average Age
  • The tenure for the Halozyme Therapeutics management team is about average.
Management Team

Helen Torley

TITLE
President
COMPENSATION
$6M
AGE
55
TENURE
5.3 yrs

Laurie Stelzer

TITLE
Senior VP & CFO
COMPENSATION
$2M
AGE
50
TENURE
3.8 yrs

Harry Leonhardt

TITLE
Senior VP
COMPENSATION
$2M
AGE
61
TENURE
4 yrs

Dimitrios Chondros

TITLE
Chief Medical Officer & Senior VP
COMPENSATION
$2M
AGE
53
TENURE
1.9 yrs

Benjamin Hickey

TITLE
Senior VP & Chief Commercial Officer
COMPENSATION
$4M
AGE
43
TENURE
0.6 yrs

Ed Gemo

TITLE
VP, Chief Information & Security Officer
TENURE
4.3 yrs

Al Kildani

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
0.4 yrs

Mike Paolucci

TITLE
Chief Human Resources Officer & VP
AGE
58
TENURE
3.8 yrs

William Fallon

TITLE
Senior VP &
COMPENSATION
$709K
AGE
61
TENURE
1.1 yrs

Homa Yeganegi

TITLE
Senior VP & Global PEGPH20 Program Lead
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Halozyme Therapeutics board of directors in years:

9.9
Average Tenure
59
Average Age
  • The tenure for the Halozyme Therapeutics board of directors is about average.
Board of Directors

Connie Matsui

TITLE
Chairperson of the Board
COMPENSATION
$305K
AGE
64

Helen Torley

TITLE
President
COMPENSATION
$6M
AGE
55
TENURE
5.3 yrs

Greg Frost

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
$68K
AGE
46
TENURE
5.3 yrs

Ken Kelley

TITLE
Independent Director
COMPENSATION
$275K
AGE
59
TENURE
14.9 yrs

Jeff Henderson

TITLE
Director
COMPENSATION
$290K
AGE
53
TENURE
3.7 yrs

Gerhard Baumgartner

TITLE
Member of Scientific Advisory Board
TENURE
14.8 yrs

Dan Von Hoff

TITLE
Member of the Scientific Advisory Board
AGE
70
TENURE
14.7 yrs

Sue Bailey

TITLE
Member of Scientific Advisory Board
AGE
74
TENURE
13.8 yrs

Jeffrey Bleil

TITLE
Member of the Advisory Board
AGE
65

Matt Posard

TITLE
Director
COMPENSATION
$270K
AGE
51
TENURE
6.1 yrs
Who owns this company?
Recent Insider Trading
  • Halozyme Therapeutics insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Feb 19 Sell Dimitrios Chondros Individual 03. Feb 19 03. Feb 19 -2,536 €14.29 €-36,243
28. Aug 18 Sell Third Security, LLC Company 24. Aug 18 28. Aug 18 -383,284 €15.55 €-5,915,467
28. Aug 18 Sell Randal Kirk Individual 24. Aug 18 28. Aug 18 -261,714 €15.55 €-4,039,199
23. Aug 18 Sell Third Security, LLC Company 21. Aug 18 23. Aug 18 -709,796 €15.97 €-10,825,586
23. Aug 18 Sell Randal Kirk Individual 21. Aug 18 23. Aug 18 -484,666 €15.97 €-7,391,974
16. Aug 18 Sell Third Security, LLC Company 14. Aug 18 16. Aug 18 -291,219 €15.24 €-4,421,272
16. Aug 18 Sell Randal Kirk Individual 14. Aug 18 16. Aug 18 -198,853 €15.24 €-3,018,976
10. Aug 18 Sell Third Security, LLC Company 08. Aug 18 10. Aug 18 -340,382 €15.35 €-5,172,297
10. Aug 18 Sell Randal Kirk Individual 08. Aug 18 10. Aug 18 -232,422 €15.35 €-3,531,784
27. Jul 18 Sell Randal Kirk Individual 25. Jul 18 27. Jul 18 -122,876 €14.86 €-1,818,231
27. Jul 18 Sell Third Security, LLC Company 25. Jul 18 27. Jul 18 -179,951 €14.86 €-2,662,787
30. Jun 18 Sell Third Security, LLC Company 27. Jun 18 29. Jun 18 -180,839 €14.86 €-2,641,692
30. Jun 18 Sell Randal Kirk Individual 27. Jun 18 29. Jun 18 -123,482 €14.86 €-1,803,822
X
Management checks
We assess Halozyme Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Halozyme Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; and ARGENX BVBA. The company was founded in 1998 and is headquartered in San Diego, California.

Details
Name: Halozyme Therapeutics, Inc.
RV7
Exchange: DB
Founded: 1998
$2,123,323,745
144,903,145
Website: http://www.halozyme.com
Address: Halozyme Therapeutics, Inc.
11388 Sorrento Valley Road,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS HALO Common Stock Nasdaq Global Select US USD 30. Jan 2003
DB RV7 Common Stock Deutsche Boerse AG DE EUR 30. Jan 2003
LSE 0J2O Common Stock London Stock Exchange GB USD 30. Jan 2003
Number of employees
Current staff
Staff numbers
281
Halozyme Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 20:34
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/10
Last earnings filing: 2019/02/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.